These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8784983)

  • 1. Lipids and progressive renal failure.
    Keane WF
    Wien Klin Wochenschr; 1996; 108(14):420-4. PubMed ID: 8784983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of lipids on the pathogenesis of progressive renal failure: role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the prevention of glomerulosclerosis.
    Guijarro C; Keane WF
    Miner Electrolyte Metab; 1996; 22(1-3):147-52. PubMed ID: 8676808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of lipids on glomerular injury and progression of renal disease.
    Keane WF
    Verh K Acad Geneeskd Belg; 1994; 56(2):91-104. PubMed ID: 8048270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholesterol synthesis inhibitors inhibit more than cholesterol synthesis.
    Kasiske BL; O'Donnell MP; Kim Y; Atluru D; Keane WF
    Kidney Int Suppl; 1994 Feb; 45():S51-3. PubMed ID: 8158898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The mevalonate pathway: importance in mesangial cell biology and glomerular disease.
    O'Donnell MP; Kasiske BL; Kim Y; Atluru D; Keane WF
    Miner Electrolyte Metab; 1993; 19(3):173-9. PubMed ID: 8232104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Is hyperlipidemia a factor in the progression of renal failure?].
    Geiger H
    Z Kardiol; 1993; 82 Suppl 4():35-8. PubMed ID: 8147060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pleiotropic effects of HMG-CoA reductase inhibitors.
    Bocan TM
    Curr Opin Investig Drugs; 2002 Sep; 3(9):1312-7. PubMed ID: 12498006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipids and the progression of renal disease.
    Keane WF; O'Donnell MP; Kasiske BL; Schmitz PG
    J Am Soc Nephrol; 1990 Nov; 1(5 Suppl 2):S69-74. PubMed ID: 16989069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of HMG-CoA reductase inhibitors (statins) on progression of kidney disease.
    Fried LF
    Kidney Int; 2008 Sep; 74(5):571-6. PubMed ID: 18528321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [HMG-CoA reductase inhibitors: anti-atherosclerotic effects other than lipid-lowering].
    Fujita R; Matsushima T
    Nihon Rinsho; 1999 Dec; 57(12):2821-5. PubMed ID: 10638219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipids and renal disease.
    Trevisan R; Dodesini AR; Lepore G
    J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S145-7. PubMed ID: 16565240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid abnormalities in the nephrotic syndrome: the therapeutic role of statins.
    Wheeler DC
    J Nephrol; 2001; 14 Suppl 4():S70-5. PubMed ID: 11798150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipids in progression of renal disease.
    Oda H; Keane WF
    Kidney Int Suppl; 1997 Nov; 62():S36-8. PubMed ID: 9350676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anti-atherosclerotic actions of HMG-CoA reductase inhibitors].
    Gmiński J; Wojakowski W
    Przegl Lek; 1997; 54(11):782-7. PubMed ID: 9501689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HMG-CoA reductase inhibition reduces the proinflammatory activation of human vascular smooth muscle cells by the terminal complement factor C5b-9.
    Viedt C; Shen W; Fei J; Kamimura M; Hänsch GM; Katus HA; Kreuzer J
    Basic Res Cardiol; 2003 Nov; 98(6):353-61. PubMed ID: 14556080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacotherapy of arteriosclerosis and its complications. Effect of ACE inhibitors and HMG-CoA-reductase inhibitors].
    Tschudi MR; Noll G; Lüscher TP
    Schweiz Med Wochenschr; 1997 Apr; 127(15):636-49. PubMed ID: 9198890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering?
    März W; Köenig W
    J Cardiovasc Risk; 2003 Jun; 10(3):169-79. PubMed ID: 12775949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunomodulatory effects of HMG-CoA reductase inhibitors.
    Danesh FR; Anel RL; Zeng L; Lomasney J; Sahai A; Kanwar YS
    Arch Immunol Ther Exp (Warsz); 2003; 51(3):139-48. PubMed ID: 12894868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy.
    Jandeleit-Dahm K; Cao Z; Cox AJ; Kelly DJ; Gilbert RE; Cooper ME
    Kidney Int Suppl; 1999 Jul; 71():S31-6. PubMed ID: 10412733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HMG-CoA reductase inhibitors in organ transplantation.
    Motomura N; Saito S; Foegh ML
    J Nephrol; 1997; 10(2):68-76. PubMed ID: 9238613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.